INTRODUCTION
Psoriasis is a common skin disease in Brazil and in the world, affecting approximately 3% of the world population. It leads to a negative impact on patient's quality of life and is associated with decreased productivity, depression, alcoholism, smoking and increased prevalence of neoplastic disease. 1, 2 It is considered a chronic inflammatory disease with a predilection for skin and joints, with multifactorial etiology and genetic and environmental influence, which is characterized by involvement of the skin by hyperproliferation and abnormal differentiation of keratinocytes, and it is immunologically mediated (Th1). The disease is associated with comorbidities, especially those related to clinical manifestations of the metabolic syndrome, beyond spondyloarthropathies, uveitis and inflammatory bowel syndromes. 1, 3 An important factor related to the pathophysiological mechanism of the disease is the increased TNF-a expression, released by activated Th1 lymphocytes, as well as most chronic inflammatory diseases. Thus, drugs that act by inhibiting TNF-a have an important role in the treatment of these diseases. Among these drugs, infliximab has been highlighted. 4 Infliximab acts neutralizing the biological activity of TNF-a by high affinity receptors with soluble and transmembrane TNF, forming an antigen-antibody complex that prevents binding of TNF-a molecule to the target cell receptor. As a result, the cell stops receiving proinflammatory stimulus and occurs the inhibition of cell proliferation, characteristic of psoriasis and other diseases mediated by TNF-a, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis and ankylosing spondylitis. 5, 6, 7 The decision to use an anti-TNF-a agent must be individual, based on the specific clinical features and the specific patient risk profile. 8 Treatment modalities for psoriasis are chosen according to disease severity, comorbidities, patient preference (including cost and convenience), effectiveness and individual assessment of response to treatment. Patients with moderate to severe psoriasis plaques should initially be treated with phototherapy and, in the presence of contraindications or failure, a systemic treatment agent should be indicated, such as infliximab. 9 The contraindications to the use of infliximab should be considered, such as hypersensitivity to the drug, known by the patient, localized or systemic active infections, infection with human immunodeficiency virus, congestive heart failure with functional class III or IV according to the New York Heart Association, history of demyelinating disease, history of cancer (except when there was no recurrence in the last 5 years and in the case of patients with basal cell carcinoma) and history of systemic lupus erythematosus. Live attenuated vaccines should not be given during treatment. 10 It is recommended updating vaccination before beginning a treatment with any anti-TNF-a agent. 10 However, various infusion reactions have been described in the literature, and the occurrence in 3-22% have been reported in psoriasis patients treated with anti-TNF-a monoclonal versus 0-2% for placebo infusion. 6, 10, 11 Adverse events can be divided into acute and late: A) Acute: occur during the infusion or until 24 hours after, such as flushing, chest tightness, nausea, dyspnea, headache, hypo/ hypertension, sweating, increased temperature and other symptoms of anaphylaxis, as urticaria and bronchospasm. 10, 12 B) Late: occur between 24 hours and 14 days after the infusion, and the main ones are arthralgia, myalgia, influenza-like symptoms, headache, fatigue, rash and urticaria.
In addition to these more common reactions, others have been reported and can occur during or after the infusion, such as induction and exacerbation of psoriasis, induction of pityriasis lichenoides chronica, formation of anti-DNA antibodies, lupus-like syndrome, malignancies, reactivation of tuberculosis primary focus, and alopecia. 1, 3, 9, [13] [14] [15] [16] [17] With all this observations, we can see that the study of adverse events is of utmost importance for its greater understanding and a subsequent attempt to minimize or control them.
OBJECTIVES
To assess the prevalence of adverse events and their characteristics in patients receiving infliximab infusion at Hospital de Base de São José do Rio Preto, comparing psoriasis patients, with or without arthritis, to patients with other chronic inflammatory diseases subjected to treatment with this drug (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis), in order to observe the peculiarities of the adverse events of each group.
METHODS
This is a retrospective cross-sectional study. Data collection was performed through the analysis of medical records of 168 patients undergoing infliximab infusion for the treatment of psoriasis, with or without arthritis, and other chronic inflammatory diseases amenable to treatment with infliximab (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis), from the Dermatology and Rheumatology Service of Hospital de Base de São José do Rio Preto, 2005-2012.
Adverse events, as well as type of disease, sex, age and number of infliximab infusions, were collected and stored in an Excel spreadsheet and subjected to statistical analysis.
The nominal qualitative variables were compared with the help of the Chi-square test and Fisher's exact test. The continuous quantitative variables with Gaussian distribution were analyzed with the help of the unpaired t test. In the case of quantitative variables without Gaussian distribution, we used the nonparametric Mann-Whitney test. All tests were applied with the assistance of the program StatsDirect Statistical Software 1.9.15.
An alpha error of 5% was admitted, being considered significant values of p≤0.050.
The study was approved by the Ethics Committee of the FAMERP of São José do Rio Preto-SP under the number CAAE 16186513.2.0000.5415.
RESULTS
Of the 168 patients evaluated using infliximab, 24 had psoriasis, 2 of them had arthritis associated with skin lesion and 144 had chronic inflammatory diseases amenable to treatment with infliximab (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis).
Of psoriasis patients, only 2 (8.3%) presented adverse events requiring discontinuation of treatment. One of them had lupus-like reaction and the other patient had an anaphylactic reaction.
Of the patients with chronic inflammatory diseases (CID), 6 (4.2%) experienced adverse events, which are: lupus-like reaction (2; 33.3%), hyperemia (1; 16.6%), papular rash (2; 33.3%) and anaphylactic reaction (1; 16.6%). In all cases, the suspension of the treatment was needed (Table 1) .
Regarding gender, 75 (44.4%) patients were men, of these 1 (1.3%) showed adverse events, and 93 (55.6%) were women, of these, 7 (7.5%) presented adverse events. Of psoriasis patients, with or without arthritis, 13 (54.2%) were women and 11 (45.8%) were men, and 1 patient in each group presented adverse events (7.6% of women and 9.0% of men). In the group of patients with other chronic inflammatory diseases, 64 were men (44.4%) and 80 (55.6%) were women, with 100% of the reactions occurring among female patients (6) ( Table 2) .
There was no statistically significant difference in gender or age when comparing the groups of diseases (psoriasis versus chronic inflammatory diseases) ( Table 2 ).
The comparative analysis using Fisher's exact test showed that there is no significant difference in the frequency of adverse events between chronic inflammatory diseases and psoriasis (p=0.408).
The analysis in each group (with psoriasis and chronic inflammatory disease) in terms of relation of age with frequency of adverse events showed no statistically significant differences by unpaired t test (p=0.379 for patients with chronic inflammatory diseases and p=0.342 for patients with psoriasis).
A comparative analysis for each group in terms of relation between gender with frequency of adverse events using the Fisher test showed that there was clinical significance only in the group of inflammatory bowel disease (p=0.050), demonstrating a higher incidence of adverse events in women, but presenting no evidence of clinical significance when performed comparative analysis in psoriasis group (p = 0.199).
Regarding the dose, using the nonparametric Mann-Whitney test, it was demonstrated that there is no relation between it and the frequency of adverse events (p=0.368).
As for the number of infusions, comparing the group with adverse events to the one without them, from the non-parametric Mann-Whitney test it was showed that the group presenting adverse events was subjected to more infusions than the other group (p=0.020) (Figure 1) , with a median of 8 infusions in the group without adverse events and 21 infusions in the group with adverse events. Regarding the frequency of infusions, among the 8 patients that presented adverse events, 75.0% (6) had delay between infusions. Statistical analysis of this data was hampered by lack of sufficient data for analysis of the total sample records.
DISCUSSION
Several studies demonstrate the infusion reactions resulting from infliximab administration in the treatment of both psoriasis and other chronic inflammatory diseases, justifying the importance of the study and prevention of such reactions.
Studies also show that the occurrence of infusion reactions in psoriasis patients treated with anti-TNF-a monoclonal is 3-22%. 10 We observed in this study an occurrence of infusion reactions of 8.3% in psoriasis patients undergoing this treatment.
Symptoms described in the literature, such as arthralgia, myalgia, influenza-like symptoms, headache, fatigue, induction and exacerbation of psoriasis, induction of pityriasis lichenoides chronica, formation of anti-DNA antibodies or reactivation of tuberculosis primary focus, wasn't observed in the results presented here. 1, 3, 10, 12, 13, 14, 17 The main infusion reaction observed in this retrospective study was lupus-like symptoms, accounting for 37.5% of the adverse events found, and this reaction has already been demonstrated in numerous studies.
The profile of infusion reactions of patients studied here does not include some reactions already described, such as the correlation between treatment with infliximab and the development of malignancies, or cases of palmoplantar pustulosis 4 induced by treatment with the monoclonal antibody in patients with psoriasis or other chronic inflammatory diseases. There were also no reports of exacerbation of clinical findings after treatment or induction of pityriasis lichenoides chronica. 13, 14, 16 There are reports in the literature of a type of adverse event called serum sickness-like, a type of hypersensitivity reaction, resulting from deposit in the tissues of circulating antigen-antibody complex formed after the infusion of the drug. 12 The clinical manifestations of this setting are rash, fever and polyarthralgia or polyarthritis, beginning after 1 to 2 weeks of the infusion. There were no reports of such reactions in patients analyzed in this study. It was observed in the study a greater number of adverse events in women who presented chronic inflammatory diseases, and 100% of patients experiencing adverse events in this group were female. Recent studies on the influence of gender on the frequency of adverse events are scarce and controversial. However, some studies corroborate the data, showing more reactions in women and highlighting the female gender as a risk factor for infusion reactions. 18, 19 We also found as a predictor of infusion reactions the number of infusions (p=0.020). This finding contradicts recent studies that observed more infusion reactions during the first infusion of the medication, showing a drop in the frequency of reactions according to the increase of the number of infusions in patients. 20, 21 We can consider as a bias of this study the absence of sufficient data to conduct comparative analysis between delayed infusions and frequency of adverse events. It is known that a long interval between infusions is a risk factor for infusion reactions, and long periods without treatment result in higher incidences of serious infusion reactions.
22,23

CONCLUSION
It can be concluded that infliximab is a safe drug, with a low percentage of adverse events, but with peculiarities in relation to the studied parameters. We demonstrated the presence of a higher percentage of adverse events in women with inflammatory bowel diseases amenable to treatment with infliximab, but there is no clinical significance in comparative analysis between gender and frequency of reactions in psoriasis group. It is also observed in the study, a higher frequency of adverse events in patients who underwent a greater number of infusions.
More studies are necessary to corroborate previous findings on the subject.q
